Innovent Biologics Commences Phase III GLORY-3 Study of Mazdutide for Metabolic Dysfunction-associated Fatty Liver Disease
China-based Innovent Biologics, Inc. (HKG: 1801) announced the first patient dosing in the Phase III...
Obesity
Novo Nordisk and Septerna Ink $2.2 Billion Deal for GPCR Drug Discovery
Denmark-based Novo Nordisk (NYSE: NVO, CPH: NOVO-B) and Septerna, Inc. (NASDAQ: SEPN) announced an exclusive...
Novo Nordisk Partners with PingAn Good Doctor to Promote Scientific Weight Loss in China
Denmark-based Novo Nordisk (NYSE: NVO, CPH: NOVO-B) has formed a strategic partnership with China’s Ping...
Genentech to Invest Over $700 Million in North Carolina Drug Manufacturing Facility
Genentech, a member of the Roche Group (SWX: ROG, OTCMKTS: RHHBY), announced plans to invest...
Hybio Partners with iCarbonX to Develop Triple Agonist for Metabolic Diseases
China-based Hybio Pharmaceutical Co., Ltd (SHE: 300199) announced a strategic partnership with compatriot firm iCarbonX...
Lepu Medical’s MWN109 Gets NMPA Clinical Approval for Diabetes and Obesity
China-based Lepu Medical Technology (Beijing) Co., Ltd (SHE: 300003), a provider of cardiovascular disease solutions,...
Zhongsheng Pharma’s RAY1225 Shows Positive Results in Phase II Trials for Weight Loss and Blood Glucose Reduction
China-based Guangdong Zhongsheng Pharmaceutical Co., Ltd. (SHE: 002317) announced positive top-line analysis results from dose...
Novo Nordisk’s Once-Daily Wegovy NDA Accepted for FDA Review
Denmark-based Novo Nordisk (NYSE: NVO) announced that its New Drug Application (NDA) filing for its...
Ascletis Pharma Announces Positive Phase Ib Results for ASC30 in Obesity Treatment
China-based Ascletis Pharma Inc. (HKG: 1672) has announced positive top-line results from a Phase Ib...
Novo Nordisk Partners with JD Healthcare to Advance Obesity and Diabetes Management
Denmark-based Novo Nordisk (NYSE: NVO) has entered into a collaboration with JD Healthcare, a subsidiary...
Novo Nordisk’s Wegovy Gets NMPA Label Update for Cardiovascular Risk Reduction
China’s National Medical Products Administration (NMPA) has approved a label update for Novo Nordisk’s (NYSE:...
Hengrui Pharmaceuticals Gains NMPA Approval for Phase Ib/II Trials of HRS-1167 and SHR-4658
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) has announced the receipt of clinical trial...
Pfizer Halts Development of Danuglipron Due to Drug-Induced Liver Injury Case
US pharmaceutical giant Pfizer Inc. (NYSE: PFE) has announced the termination of development for its...
Novo Nordisk Invests BRL 6.4 Billion in Brazilian Manufacturing Expansion for Obesity Drugs
Denmark-based Novo Nordisk A/S (NYSE: NVO) has announced a significant investment of BRL 6.4 billion...
Sinopep-Allsino Partners with Gulf Pharmaceutical for Semaglutide API Supply
Jiangsu-based Contract Development and Manufacturing Organization (CDMO) Sinopep-Allsino Biopharmaceutical Co., Ltd (SHA: 688076) has signed...
Novo Nordisk Partners with Tencent Healthcare for Weight Management Initiative in China
In alignment with China’s “Weight Management Year” initiative, Denmark-based Novo Nordisk A/S (NYSE: NVO) has...
Ascletis Pharma’s ASC30 Shows Positive Results in US Phase Ib Obesity Study
China-based Ascletis Pharma Inc. (HKG: 1672) announced positive interim results from a Phase Ib study...
Laekna Submits Revised Protocol for LAE102 Obesity Trial with Eli Lilly
Sino-US biotech Laekna Therapeutics (HKG: 2105) announced the submission of a revised clinical protocol to...
Hengrui Pharmaceuticals Gets NMPA Green Light for HRS-1738 and HRS-5817 Clinical Trials
Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced receiving approval from the National Medical Products...
United Laboratories Inks Global Licensing Deal with Novo Nordisk for Obesity Drug
Hong Kong-based United Laboratories International Holdings Ltd (HKG: 3933) has entered into a licensing agreement...